Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash

Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8

Venus Remedies joins United Nations Global Compact

This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery

Solara Active Pharma Sciences posts Q4 FY25 consolidated loss at Rs. 2.10 Cr

The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025

Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001 for relapsed/refractory multiple myeloma

IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

The Subsidiary has received one inspectional observation in Form 483

Nureca receives approval for new manufacturing facility

This unit will focus on the manufacturing of health and wellness equipment

Carbogen Amcis Shanghai site receives drug manufacturing license from Chinese NMPA

GSK’s blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma

Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed

Zydus Medtech inks pact with Braile Biomedica to commercialise TAVI technology

Zydus MedTech gets rights to market the innovative Transcatheter Aortic Valve Implantation (TAVI) technology in India, Europe and other select markets

Sigachi receives environmental clearance for greenfield Dahej manufacturing facility

The plant will have installed production capacity of 3,120 MT/month